An Overview of the Multidisciplinary Management of Dupuytren's and Ledderhose Diseases

Dupuytren's and Ledderhose Diseases are very prevalent hyperproliferative disorders of the hands and feet that affect 3-5% of the population. When progressive, these conditions can result in pain, debility and loss of function. Radiation therapy is commonly utilized in Europe for the treatment of both of these conditions but much less commonly employed in North America. This presentation reviews the pathophysiology, diagnosis and management of Dupuytren's and Ledderhose Diseases and provide an overview of the expanding role of the radiation oncologist in the longitudinal and multidisciplinary management of these patients.

Presenters: Gopal K. Bajaj, MD, MBA, FASTRO and M. Heinrich Seegenschmiedt, MD, PhD
Moderator: Bobby N. Koneru, MD, FASTRO

This session was originally presented and recorded as a live webinar on September 18, 2024.

Target Audience

This activity is designed to meet the interests of radiation oncologists, radiation physicists, radiation dosimetrists, radiation biologists, radiation therapists, medical oncologists, nurses, surgeons, pathologists, orthopedists, endocrinologists, primary care physicians, and radiation oncology residents.

Learning Objectives

Upon completion of this activity, participants should be able to do the following:

  1. Describe and understand the unique pathophysiology of Dupuytren’s and Ledderhose Disease.
  2. Analyze current data on the role of radiotherapy in the management of Dupuytren’s and Ledderhose Disease.
  3. Discuss the role of the radiation oncologist in the multidisciplinary management of Dupuytren’s and Ledderhose Disease.
Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.50 Certificate of Attendance
    This activity was designated for 1.50 AMA PRA Category 1 Credit™.
Course opens: 
07/22/2024
Course expires: 
10/09/2026
Cost:
$0.00
Rating: 
0
  • Gopal K. Bajaj, MD, MBA, FASTRO is Partner/President of Radiation Oncology Associates of the Northern Capital Region. Dr. Bajaj has ownership equity and partnership as Co-CM0 of Theralife Clinics North America; ownership equity in Bajaj Ventures LLC; and a partnership in Totipotent Capital.
  • M. Heinrich Seegenschmiedt, MD, PhD is employed by ERGEA/RadioOnkologieNetzwerk.
  • Bobby N. Koneru, MD, FASTRO is employed by FHN Memorial Hospital and Loyola University Stritch School of Medicine. Dr. Koneru serves on the Clinical Advisory Board of the International Organisation for Radiotherapy for Benign Conditions. 

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.50 Certificate of Attendance
    This activity was designated for 1.50 AMA PRA Category 1 Credit™.

Price

Cost:
$0.00
Please login or register to take this course.